Clinical trials: Thin Basement Membrane Disease
Alport Syndrome, Hereditary Kidney Disease
Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome
The hereditary type IV collagen disease Alport syndrome leads to kidney failure early in life. Currently there are no specific medications approved for treatment, however, several therapies have been evaluated preclinically and…
- Conditions
- Alport Syndrome, Hereditary Kidney Disease, Pediatric Kidney Disease, Thin Basement Membrane Disease
- Trial name
- Alport-XXL (NCT02378805)
- Testing
- ACE-inhibitor, Angiotensin-receptor blocker (ARB), HMG-Coenzyme inhibitor (statin)
- Where
- Germany
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- University Hospital Goettingen
Collagen Type-4 Nephropathies
Enalapril in Collagen Type 4 Nephropathy
Background: Collagen IV-related nephropathies can lead to End Stage Renal Disease. Experimental studies have shown renin angiotensin aldosterone system blockade can reduce proteinuria and preserve renal function.
- Trial name
- NCT01465126
- Volunteers
- 19 people
- Sponsor
- University of Sao Paulo
Alport Syndrome, Thin Basement Membrane Disease
Albuminuria Lowering Effect of Dapagliflozin, Spironolactone and Their Combination in Adult Patients With Alport Syndrome (COMBINE-ALPORT)
Alport syndrome (AS) is one of the most common monogenic kidney disorders, oftentimes leading to end-stage kidney disease (ESKD).
- Conditions
- Alport Syndrome, Thin Basement Membrane Disease, Alport Nephropathy
- Trial name
- COMBINE-ALPORT (NCT06499948)
- Testing
- Treatment with Spironolactone followed by Dapagliflozin followed by their combination, Treatment with Dapagliflozin followed by Spironolactone followed by their combination
- Where
- Romania
- Volunteers
- 12 people
- Sponsor
- Stefan Lujinschi
Alport Syndrome, Thin Basement Membrane Disease
ASF Alport Patient Registry
Alport Syndrome Foundation's (ASF's) Alport Patient Registry (the Registry) is open to individuals living with Alport syndrome in the United States (US) and US territories and outlying islands.
- Conditions
- Alport Syndrome, Thin Basement Membrane Disease, Hereditary Nephritis
- Trial name
- NCT06526741
- Testing
- Longitudinal data collection
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- Alport Syndrome Foundation
Proteinuria
Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria
The primary objective of this study is to assess the impact of proteinuria on the pharmacokinetic (PK) of a single dose of ALXN1720 in participants with proteinuria.
- Trial name
- NCT05314231
- Testing
- ALXN1720
- Where
- 2 sites in South Korea
- Volunteers
- 13 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis
National Registry of Rare Kidney Diseases
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research.
- Conditions
- Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis, AHL Amyloidosis, AL Amyloidosis
- Trial name
- RaDaR (NCT06065852)
- Where
- United Kingdom
- Volunteers
- 35,000 people
- Sponsor
- UK Kidney Association